Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DT-001
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Fountain Healthcare Partners
Deal Size : $44.0 million
Deal Type : Series A Financing
Dualyx Raises 40 Million To Progress Treg Therapies For Autoimmune Diseases Into The Clinic
Details : The use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting the highly attractive TNF receptor 2 (TNFR2) and widely regarded as a master control switch in immune modulation, as well as its pipeline of Treg...
Product Name : DT-001
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : DT-001
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Fountain Healthcare Partners
Deal Size : $44.0 million
Deal Type : Series A Financing